134 related articles for article (PubMed ID: 30026328)
21. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity.
Leão M; Gomes S; Soares J; Bessa C; Maciel C; Ciribilli Y; Pereira C; Inga A; Saraiva L
FEBS J; 2013 Dec; 280(24):6498-507. PubMed ID: 24119020
[TBL] [Abstract][Full Text] [Related]
22. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
23. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
24. [NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].
Shuvalov OY; Fedorova OA; Petukhov AV; Daks AA; Vasilieva EA; Grigorieva TA; Ivanov GS; Barlev NA
Tsitologiia; 2015; 57(12):847-54. PubMed ID: 26995961
[TBL] [Abstract][Full Text] [Related]
25. The small molecule AU14022 promotes colorectal cancer cell death via p53-mediated G2/M-phase arrest and mitochondria-mediated apoptosis.
Ryu H; Nam KY; Kim JS; Hwang SG; Song JY; Ahn J
J Cell Physiol; 2018 Jun; 233(6):4666-4676. PubMed ID: 29030986
[TBL] [Abstract][Full Text] [Related]
26. Synergistic suppression of prostatic cancer cells by coexpression of both murine double minute 2 small interfering RNA and wild-type p53 gene in vitro and in vivo.
Ji K; Wang B; Shao YT; Zhang L; Liu YN; Shao C; Li XJ; Li X; Hu JD; Zhao XJ; Xu DQ; Li Y; Cai L
J Pharmacol Exp Ther; 2011 Jul; 338(1):173-83. PubMed ID: 21444629
[TBL] [Abstract][Full Text] [Related]
27. Structure-based designing efficient peptides based on p53 binding site residues to disrupt p53-MDM2/X interaction.
Rasafar N; Barzegar A; Mehdizadeh Aghdam E
Sci Rep; 2020 Jul; 10(1):11449. PubMed ID: 32651397
[TBL] [Abstract][Full Text] [Related]
28. Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogene.
Kong Y; Lu ZL; Wang JJ; Zhou R; Guo J; Liu J; Sun HL; Wang H; Song W; Yang J; Xu HX
Oncol Rep; 2016 Sep; 36(3):1447-56. PubMed ID: 27432230
[TBL] [Abstract][Full Text] [Related]
29. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.
Moreno-Smith M; Lakoma A; Chen Z; Tao L; Scorsone KA; Schild L; Aviles-Padilla K; Nikzad R; Zhang Y; Chakraborty R; Molenaar JJ; Vasudevan SA; Sheehan V; Kim ES; Paust S; Shohet JM; Barbieri E
Clin Cancer Res; 2017 Nov; 23(21):6629-6639. PubMed ID: 28821555
[No Abstract] [Full Text] [Related]
30. MDM2/MDMX inhibitor peptide: WO2008106507.
Macchiarulo A; Pellicciari R
Expert Opin Ther Pat; 2009 May; 19(5):721-6. PubMed ID: 19441944
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer.
Zhang Y; Shi Y; Li X; Du W; Luo G; Gou Y; Wang X; Guo X; Liu J; Ding J; Wu K; Fan D
J Gene Med; 2010 Feb; 12(2):147-56. PubMed ID: 20020415
[TBL] [Abstract][Full Text] [Related]
32. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
33. Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells.
Chiu SJ; Hsaio CH; Tseng HH; Su YH; Shih WL; Lee JW; Chuah JQ
Biochem Biophys Res Commun; 2010 Apr; 394(3):774-9. PubMed ID: 20227390
[TBL] [Abstract][Full Text] [Related]
34. CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo.
He X; Kong X; Yan J; Yan J; Zhang Y; Wu Q; Chang Y; Shang H; Dou Q; Song Y; Liu F
Tumour Biol; 2015 Mar; 36(3):1437-44. PubMed ID: 25663456
[TBL] [Abstract][Full Text] [Related]
35. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
36. Relationships between G1 arrest and stability of the p53 and p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma cells.
Bae I; Fan S; Bhatia K; Kohn KW; Fornace AJ; O'Connor PM
Cancer Res; 1995 Jun; 55(11):2387-93. PubMed ID: 7757991
[TBL] [Abstract][Full Text] [Related]
37. MDMX regulation of p53 response to ribosomal stress.
Gilkes DM; Chen L; Chen J
EMBO J; 2006 Nov; 25(23):5614-25. PubMed ID: 17110929
[TBL] [Abstract][Full Text] [Related]
38. Modulating Survivin as a Radioresistant Factor, Caspase-3, and Apoptosis by Omega-3 Docosahexaenoic Acid Sensitizes Mutant-p53 Colorectal Cancer Cells to γ-Irradiation.
Hosseini F; Sam MR; Jabbari N; Mozdarani H
Cancer Biother Radiopharm; 2018 Nov; 33(9):387-395. PubMed ID: 30395490
[TBL] [Abstract][Full Text] [Related]
39. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells.
Capoulade C; Bressac-de Paillerets B; Lefrère I; Ronsin M; Feunteun J; Tursz T; Wiels J
Oncogene; 1998 Mar; 16(12):1603-10. PubMed ID: 9569028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
